Prosecution Insights
Last updated: October 04, 2026
Application No. 18/843,652

METHOD FOR PREVENTING OR TREATING HEARING LOSS

Non-Final OA §102
Filed
Sep 03, 2024
Priority
Mar 04, 2022 — provisional 63/316,894 +1 more
Examiner
WEDDINGTON, KEVIN E
Art Unit
Tech Center
Assignee
Mackay Medical College
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1108 granted / 1473 resolved
+15.2% vs TC avg
Moderate +10% lift
Without
With
+9.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
42 currently pending
Career history
1493
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
28.3%
-11.7% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
28.6%
-11.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1473 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are presented for examination. Applicant’s drawings, information disclosure statement, and preliminary amendment filed September 3, 2024 have been received and entered. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Allowable Subject Matter Claims 1-9 and 11-20 are allowable. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 10 is rejected under 35 U.S.C. 102(a)(2) as being anticipated by Prasad et al. (7,635,469 B2). Prasad et al. teach a hearing health micronutrient formulation consisting essentially of natural mixed carotenoids selected from fucoxanthin (see column 16, claim 2, line 9). Clearly, the cited reference teaches the administering of natural mixed carotenoids such as fucoxanthin for hearing health would inherently treat hearing loss. Claim 10 is not allowed. The reference listed on the enclosed PTO-892 is cited to show the state of the art and applicant’s own work. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN E WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached M-F 1:30-10:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeff Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. KEVIN E. WEDDINGTON Primary Examiner Art Unit 1629 /KEVIN E WEDDINGTON/Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Sep 03, 2024
Application Filed
Aug 24, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746215
MONO- AND BIS-NITROSYLATED PROPANEDIOLS FOR THERAPEUTIC USE
3y 10m to grant Granted Sep 29, 2026
Patent 12746235
USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN
1y 7m to grant Granted Sep 29, 2026
Patent 12740957
COMPOSITION AND METHOD TO REDUCE LIVER FAT AND CIRCULATING TRIACYLGLYCEROLS
3y 4m to grant Granted Sep 22, 2026
Patent 12734159
METHODS OF TREATING SPINAL CORD INJURY OR DAMAGE
3y 0m to grant Granted Sep 15, 2026
Patent 12714688
MARGARIC ACID DECREASES PIEZ02-MEDIATED PAIN
4y 0m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
85%
With Interview (+9.8%)
2y 5m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1473 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month